4 stories mentioning TYO:4565Updated 12d ago
Every FINWIRES story that references TYO:4565, newest first.
Nxera Pharma (TYO:4565) will receive a $8.6 million milestone payment from Centessa Pharmaceuticals, a unit of American pharmaceutical company Eli Lilly, following a late-stage development milestone, according to a Thursday filing with the Tokyo Exchange.The biopharmaceutical company said the milestones are linked to Centessa's selective orexin receptor 2 agonist portfolio under its research collaboration with Centessa.
Nxera Pharma's (TYO:4565) will receive $10 million after partner Neurocrine Biosciences won U.S. regulatory approval for a mid-stage Alzheimer's drug study.The drug, discovered using Nxera's proprietary platform, is an oral treatment designed to target cognition in Alzheimer's patients, according to a Tokyo bourse filing on Wednesday.This is the third compound from the partnership to reach Phase 2 testing, with the first already in late-stage trials and a second also progressing through mid-stage studies.Nxera keeps the rights to develop and sell the drug in Japan.
Nxera Pharma (TYO:4565) said it will receive a $10 million milestone payment from AbbVie under their neurological disease research partnership, according to a Monday filing on the Tokyo Stock Exchange.The payment marks the third milestone in the collaboration and is tied to the identification of validated drug candidates targeting neurological conditions.Under the agreement, Nxera is eligible for up to $1.2 billion in total milestones, along with tiered royalties on future sales. The partnership, launched in 2022, uses Nxera's GPCR-focused discovery platform to develop new therapies for unmet neurological needs.
Nxera Pharma (TYO:4565) said its partner Neurocrine Biosciences has dosed the first patient in a mid-stage trial of an experimental schizophrenia treatment, triggering a $22.5 million milestone payment to the Japanese drugmaker, according to a Monday filing on the Tokyo Stock Exchange.The Phase 2 study will evaluate NBI-1117570, an oral dual muscarinic M1/M4 receptor agonist discovered by Nxera, in adults with schizophrenia requiring in-patient care. The payment will be booked as revenue in the first quarter of fiscal 2026, Nxera said.The randomized, double-blind, placebo-controlled trial is expected to enroll about 120 patients. Its main goal is to measure changes in the Positive and Negative Syndrome Scale (PANSS) total score, a standard tool used to assess symptom severity, while also tracking safety and tolerability.NBI-1117570 targets muscarinic acetylcholine receptors in the brain, with M1 linked to cognitive function and M4 associated with psychosis. The compound was developed using Nxera's NxWave drug discovery platform and is being advanced under a multi-program partnership with Neurocrine.
